Effects of Renal Denervation on Ambulatory Blood Pressure Measurements in Patients With Resistant Arterial Hypertension

The sympathetic nervous system is an important factor in hypertension. In patients suffering from resistant hypertension, transfemoral renal sympathetic denervation (RDN) reduces office blood pressure (BP) values.

[1]  R. Schmieder,et al.  Ambulatory blood pressure monitoring: is it mandatory for blood pressure control in treated hypertensive patients?: prospective observational study. , 2013, International journal of cardiology.

[2]  H. Krum,et al.  Ambulatory Blood Pressure Changes After Renal Sympathetic Denervation in Patients With Resistant Hypertension , 2013, Circulation.

[3]  Jennifer Taylor,et al.  2013 ESH/ESC guidelines for the management of arterial hypertension. , 2013, European heart journal.

[4]  F. Leisch,et al.  Redo of percutaneous renal denervation in a patient with recurrent resistant hypertension after primary treatment success , 2013, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[5]  R. Schmieder,et al.  Ruling out secondary causes of hypertension. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[6]  G. Parati,et al.  Updated ESH position paper on interventional therapy of resistant hypertension. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[7]  G. Mancia,et al.  Home and ambulatory blood pressure in resistant hypertension. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  M. Böhm,et al.  Response and non-response to renal denervation: who is the ideal candidate? , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[9]  D. Cohen,et al.  Renal Denervation: A Potential New Treatment for Severe Hypertension , 2013, Clinical cardiology.

[10]  Cheree James,et al.  Autonomic markers of emotional processing: skin sympathetic nerve activity in humans during exposure to emotionally charged images , 2012, Front. Physio..

[11]  Deepak L. Bhatt,et al.  Catheter‐Based Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPLICITY HTN‐3 Trial , 2012, Clinical cardiology.

[12]  Gianfranco Parati,et al.  The human sympathetic nervous system: its relevance in hypertension and heart failure. , 2012, European heart journal.

[13]  M. Gawaz,et al.  Effects of Renal Sympathetic Denervation on 24-hour Blood Pressure Variability , 2012, Front. Physio..

[14]  M. Böhm,et al.  Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. , 2012, Journal of the American College of Cardiology.

[15]  G. Bobrie,et al.  Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension. , 2012, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[16]  V. Somers,et al.  Effects of Renal Sympathetic Denervation on Blood Pressure, Sleep Apnea Course, and Glycemic Control in Patients With Resistant Hypertension and Sleep Apnea , 2011, Hypertension.

[17]  R. Hermida,et al.  Decreasing sleep-time blood pressure determined by ambulatory monitoring reduces cardiovascular risk. , 2011, Journal of the American College of Cardiology.

[18]  H. Krum,et al.  Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study , 2011, Circulation.

[19]  Symplicity Htn Investigators,et al.  Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: Durability of Blood Pressure Reduction Out to 24 Months , 2011, Hypertension.

[20]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[21]  Guido Grassi,et al.  Sympathetic neural activity in hypertension and related diseases. , 2010, American journal of hypertension.

[22]  G. Dibona,et al.  Translational medicine: the antihypertensive effect of renal denervation. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[23]  Henry Krum,et al.  Renal denervation as a therapeutic approach for hypertension: novel implications for an old concept. , 2009, Hypertension.

[24]  S. Julius,et al.  The complex interaction between overweight, hypertension, and sympathetic overactivity. , 2009, Journal of the American Society of Hypertension : JASH.

[25]  K. Kario,et al.  24-Hour Blood Pressure Control – A Predictor for Clinical Outcomes , 2009 .

[26]  Michael Böhm,et al.  2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). , 2007, Journal of hypertension.

[27]  A. Dominiczak,et al.  2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) , 2007, European heart journal.

[28]  Roberto Sega,et al.  Long-Term Risk of Mortality Associated With Selective and Combined Elevation in Office, Home, and Ambulatory Blood Pressure , 2006, Hypertension.

[29]  Paul A. Smith,et al.  Relationship between central sympathetic activity and stages of human hypertension. , 2004, American journal of hypertension.

[30]  G. Parati,et al.  Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis , 2004, Journal of hypertension.

[31]  Peter W de Leeuw,et al.  Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. , 2003, The New England journal of medicine.

[32]  G. Stergiou,et al.  Reproducibility of home, ambulatory, and clinic blood pressure: implications for the design of trials for the assessment of antihypertensive drug efficacy. , 2001, American journal of hypertension.

[33]  G Parati,et al.  Ambulatory Blood Pressure Monitoring and Organ Damage , 2000, Hypertension.

[34]  M. Kikuya,et al.  Prediction of stroke by ambulatory blood pressure monitoring versus screening blood pressure measurements in a general population: the Ohasama study , 2000, Journal of hypertension.

[35]  L. Ruilope,et al.  Prognostic value of ambulatory blood pressure monitoring in refractory hypertension: a prospective study. , 1998, Hypertension.

[36]  J. Born,et al.  Plasma epinephrine and norepinephrine concentrations of healthy humans associated with nighttime sleep and morning arousal. , 1997, Hypertension.

[37]  R. Kirkpatrick,et al.  Ambulatory Blood Pressure Monitoring , 1993, The Journal of the American Board of Family Medicine.

[38]  Julio A. Panza,et al.  Circadian variation in vascular tone and its relation to α-sympathetic vasoconstrictor activity , 1991 .

[39]  J. Laragh,et al.  The reproducibility of average ambulatory, home, and clinic pressures. , 1988, Hypertension.

[40]  W. Cooke,et al.  Sympathectomy in the treatment of hypertension; review of 122 cases. , 1953, Lancet.

[41]  H. Krum,et al.  Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. , 2012, Circulation.

[42]  M. Gus.  Renal sympathetic denervation in patients with treatment- resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial , 2011 .

[43]  J. Manson,et al.  Prospective Study of , 2007 .

[44]  G. Bakris,et al.  Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. , 2006, American Heart Journal.

[45]  Ettore Ambrosioni,et al.  ESH/ESC guidelines for the management of arterial hypertension: how to implement in daily clinical practice , 2004 .

[46]  A. Quyyumi,et al.  Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. , 1991, The New England journal of medicine.

[47]  M. Elian,et al.  Letter: Motor-neurone disease in Israel. , 1975, Lancet.